Inserm Transfert, your partner for value creation and technology transfer

Inserm Transfert, founded in 2000, is the private subsidiary of Inserm, specialized in life sciences technology transfer and collaborative research projects funding. It works under a Public service Delegation Agreement (DSP).

0

patent families*

0

number of contracts and licenses*

* For the year 2020

0

millions of euros invested in Proof of concept

0

projects detected*

Serving research

The company supports Inserm research units and researchers in the process undertaken to create value from their work. Its actions are part of the translational continuum, from basic and technological research to clinical development, with the aim of creating economic and societal value.

Plan France Relance

L’Inserm et la mesure de la Préservation de l'emploi de R&D en Santé

Are you a Researcher?

Protecting my results
Involving companies
Funding my project
Thinking about entrepreneurship

Are you a Company?

A response dedicated to your needs
Our strategic areas of innovation
An exceptional offer
Plan France Relance en

Are you an Investor?

Investors

News

23 Jul 2021

Plus de 56,6 Millions de revenus générés en 2020 pour la recherche de l’@Inserm et de ses partenaires de mixité. Re… https://t.co/dJzCfNgZeK

12 Jul 2021

Concours #iLab2021 Félicitations aux 7 Lauréats issus de l’@Inserm et ayant bénéficié d’un accompagnement d’… https://t.co/sxw6bPwJDt

09 Jul 2021

«Les défis de la valorisation de la recherche et le capital-risque» avec Pascale AUGÉ @InsermTransfert, Anne OSDOIT… https://t.co/IdlCyIFFCd

08 Jul 2021

RT @Inserm: La #COVID19, un impact sur la fertilité, vraiment ? 🤔 Notre nouveau #CanalDétox fait le point sur les connaissances scientifi…

05 Jul 2021

@InsermTransfert présente ses résultats 2020 : des actions de soutien contre le #Covid, des réussites entrepreneuri… https://t.co/iY7JWreW5U

01 Jul 2021

Vive l’entrepreneuriat au service de l’innovation et de la santé ! @InsermTransfert, chef de file du consortium… https://t.co/Vy9YJw8mxM

01 Jul 2021

Construire une souveraineté sanitaire : Webinaire de l’@IHEST Session sur « les défis de la valorisation de la rech… https://t.co/mZTf4RqUUE

25 Jun 2021

RT @AmgenFrance: 👁️Pascale Auge, CEO de @InsermTransfert donne son avis sur le #ThinkTank et la thématique "Terre de champions" à laquelle…

25 Jun 2021

Belle valorisation de la recherche: Corlieve Therapeutics (épilepsie du lobe temporal) fondée par Valérie Crépel Ch… https://t.co/YOJPwynGgC

16 Jun 2021

RT @VivaTech: Europe’s biggest startup and tech event is here! Online and in person, it's time to say hello to DAY 1 of #VivaTech. It feels…

16 Jun 2021

@InsermTransfert est partenaire du 9th Antibody Industrial Symposium @congress_ais qui se déroulera du 22 au 25 jui… https://t.co/wiviOJ4Bkc

16 Jun 2021

RT @Inserm: Donnez du sens à votre métier, rejoignez la recherche en #santé. L’Inserm recrute par concours 83 personnels scientifiques et a…

10 Jun 2021

2ème Medicen R&D, « les rendez-vous des AAP Santé », Olivier Bignolais @InsermTransfert, Chantal Vernis @CNRS, Nic… https://t.co/fMixRN425C

08 Jun 2021

2ème jour du @CongresCURIE Pascale Augé anime la session "Investissement Early stage dans les startups deep tech",… https://t.co/RXabtAoTS4

07 Jun 2021

La détection de projet à l'honneur au @CongresCURIE ! https://t.co/MiOc4AWUki https://t.co/WFjTV7tUqY

07 Jun 2021

@CongresCURIE, aujourd'hui à 15h30 : point sur la détection de projet par Hervé Coste, directeur expertise et sourc… https://t.co/pEuSBJ6ubO

07 Jun 2021

"L'investissement pour les nuls" Intervention de Pascale Augé, @InsermTransfert, en compagnie de Thierry Merquiol e… https://t.co/4MBPFGRqR2

04 Jun 2021

Inserm Transfert est partenaire du projet collaboratif AB-Direct Antibiotic Distribution and Recovery in Tissue. Ob… https://t.co/XU9de1ZLrG

02 Jun 2021

RT @EnsatHt: [📣Announcement📣 ] @ENS@T-HT partners submitted a #newpatent application to develop a multi-omics signature and use of identi…

28 May 2021

Pascale Augé, Présidente du Directoire d'@InsermTransfert participe à 2 interventions lors du @CongresCURIE : - 7 j… https://t.co/8thcw61h1C

Collaborative projects

High-quality support for a research excellence.

CBIG-SCREEN

H2020

CBIG-SCREEN aims to tackle inequality in cervical cancer screening (CCS) continuum. Though CCS programmes drastically reduce cervical cancer mortality, they remain largely inaccessible and ...

EHVA

H2020

 the European HIV Vaccine Alliance (EHVA) program will develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines.

...

EJP-RD

H2020

The European Joint Program on Rare Diseases brings over 130 institutions from 35 countries 27 EU Member States (Austria, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, Germany, ...

REMEDIA

H2020

The overall objective of the REMEDIA project is to determine how and to what extent the exposome affects the severity and morbidity of Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis ...

CARDIATEAM

IMI

Diabetic patients are 2.5 times more likely to develop heart failure than people without diabetes. In many patients, the diabetes causes a type of heart dysfunction called cardiomyopathy, which is ...

ENSAT-HT

H2020

This project will develop and evaluate an omics-based stratified health promotion program for patients with endocrine forms of hypertension.

...

COSY

RHU

The aim of our project is to transform the outcome and the medical care of patients with overgrowth syndromes (OS)

...

EU-TRAIN

H2020

"End stage renal diseases affect more than 3,900,000 patients worldwide with approximately 6% growth rate in 2016. Kidney transplantation is currently the best therapeutic option with around ...

KTD INNOV

RHU

"KTD-Innov combines molecular medicine (MM) and health information technology (HIT) to deliver a precision immune monitoring and diagnosis system applied in kidney transplantation: the Integrative ...

HUGODECA

H2020

"The HUGODECA project is a European funded research initiative investigating how human gonads (either an ovary or a testis) develop in the embryo in order to understand how the initially bipotential ...

CARMMA

RHU

CARMMA is based on the hypothesis that obesity co-morbidities are associated with an early senescence of adipose tissue (AT). The main objective of CARMMA is to determine the common and central ...

iVASC

RHU

iVASC est un consortium de chercheurs, de cliniciens et d’industriels, qui vise à mettre au point de nouveaux outils de recherche dans le domaine de l’athérothrombose et à les appliquer à ...

CARE

IMI

The CARE consortium is a coalition of 37 academic institutions, pharmaceutical companies and non-profit research organizations whose main objectives are the development of therapeutics (i) to ...

TheraLymph

H2020

Lymphedema is a disabling condition of localised accumulation of fluid in a tissue caused by a compromised lymphatic system. It is an incurable disease that affects millions of people worldwide and...

AB-DiRecT

IMI

Developing antibacterials for resistant infections. An alarming rise globally in antibiotic-resistant infections and a search for new solutions is the motivational force behind project AB-DiRecT. ...

IP-CURE-B

H2020

To develop novel curative concepts for chronic hepatitis B (CHB). The project aims to improve the cure rate of CHB by boosting innate immunity with immune modulators and stimulating adaptive immune...

VHFMoDRAD

IMI

VHFMoDRAD will develop and deliver rapid and point-of-care singel/multiplex diagnostic tool(s) that will significantly increase our capacity to handle outbreaks with Filoviruses and other viral ...

CCHFVaccine

H2020

The general aim of the CCHFVaccine project is to develop and deliver a vaccine, which can significantly increase our capacity to control the situation of Crimean Congo Haemorrhagic fever (CCHF) ...

ERINHA-Advance

H2020

One of the great challenges of the 21st century is to develop the capacity to prevent and react to outbreaks caused by highly pathogenic human and animal microorganisms, which are generally ...

EU-JAV

EU health programme

EU-JAV brings together the European Commission, health ministries, international policymakers and organisations, institutes, universities from 20 countries and a wide range of stakeholders, including ...

ZIKAlliance

H2020

ZIKAlliance is a multinational, multi-disciplinary research consortium comprised of 54 partners worldwide. It investigates clinical, fundamental, environmental and social aspects of ZIKV infection, in...

EBOVAC2

IMI

" The main objective of EBOVAC 2 is to provide extensive and robust data on the safety, immunogenicity and efficacy of the Ad26.ZEBOV and MVA-BN-Filo vaccine....

R-LINK

H2020

The main objective of this study is to identify the eligibility criteria for treatment with lithium in bipolar I disorders (BDI) in terms of response, safety and tolerability. R-LiNK proposes a ...

QUID NASH

RHU

The main aim of the QUID-NASH program is to develop a virtual liver biopsy (non invasive) for the diagnosis and staging of NASH (Non Alcoholic SteatoHepatitis) in patients with type 2 diabetes,...

PREVAC-UP

The project PREVAC-UP is built around the PREVAC consortium. Its two primary objectives are to determine (i) the long-term immunogenicity and safety and (ii) durability of humoral and cellular ...

PREMSTEM

H2020

PREMSTEM aims to validate umbilical cord derived human mesenchymal stem cells as a regenerative therapy for encephalopathy of prematurity to improve the quality of life for preterm infants and reduce ...

OBERON

H2020

The OBERON project will build an integrated approach for testing and assessment (IATA) to detect endocrine disruptors-related metabolic disorders by developing, improving and validating a battery of ...

MIROCALS

H2020

Efficacy and safety of low-dose IL2 (ld-IL2) as a Treg enhancer for anti-neuroinflammatory therapy in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients...

miniNO

H2020

The miniNO project will conduct out pioneering research on the connection between alterations in minipuberty and infantile nitric oxide (NO) signaling in the brain, and comorbidities that appear later...

MEDIT-AGEING

H2020

As the number of older people in Europe grows, increasing healthy life years is a priority. Cognitive decline, dementia (e.g. Alzheimer’s disease, AD), sleep disturbances and depression, all ...

MAD-CoV 2

IMI

The overall aim of MAD-CoV 2 project is to develop and deliver a treatment for COVID-19 patients, which will significantly increase our capacity to handle the current outbreak of SARS-CoV-2. In ...

JPsustaiND

H2020

The overall aim of JPsustaiND is to support the development and extension of the capacities of the EU Joint Programming Initiative on Neurodegenerative Diseases, in particular Alzheimer's (JPND). ...

JPcofuND2

H2020

With the objective of promoting research aimed at changing the trajectory of these debilitating diseases, JPco-fuND 2 launched in January 2019, a joint transnational call supported by 27 countries for...

JPco-fuND

H2020

This initiative launched a joint transnational call for proposals, as a joint effort of 20 countries, aimed at supporting international research collaborations in three JPND priority areas: ...

HERA

H2020

HERA will set the priorities for an environment and health research agenda in the EU by adopting a holistic and systemic approach in the face of global environmental changes. Research will support ...

HBM4EU

H2020

HBM4EU is a joint effort of 30 countries, the European Environment Agency and the European Commission, co-funded under Horizon 2020. The initiative is coordinating and advancing human biomonitoring in...

FAIR-PARK-II

H2020

"FAIR PARK II will primarily investigate the effects of an iron chelation therapy on the progression of handicap in Parkinson's disease.
The project will run for five years (2015 - 2020) and ...

FAIR

H2020

The project aims to assess an adjunct to antibiotic therapy as an emerging concept to overcome antimicrobial resistance in pneumonia. The research focuses on the unique immunomodulator flagellin that ...

EU-RESPONSE

H2020

The overall objective of this 5-year project is to build a multinational, adaptive European COVID-19 and emerging infectious diseases trial network, based on existing initiatives, experience and ...

EBRA

H2020

EBRA aims at reducing the fragmentation and duplication of research efforts and at fostering synergies through enhanced coordination of brain research efforts at the EU and global level....